SCHEMBL6745666

SCHEMBL6745666

COc1cc(CNc2nc(C)nc(C)c2Cl)cc(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
ALDH1A1 P00352 3/20 0.45
HTT P42858 2/20 0.45
POLB P06746 1/20 0.45
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RECQL P46063 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CDK1 P06493 1/20 0.41
LMNA P02545 1/20 0.40
MAPK1 P28482 2/20 0.40
DHFR P00374 1/20 0.39
BCDIN3D Q7Z5W3 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 1/20 0.37
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6744001 0.91 CALM1 (0.40) MAPTALDH1A1HTTPOLBKDM4E
SCHEMBL6744013 0.79 HSD17B10 (0.37) HSD17B10LMNAKMT2A
SCHEMBL6742014 0.79 TSHR (0.48) POLBMAPK1BCDIN3DMEN1KMT2A
SCHEMBL6739468 0.77 ALDH1A1 (0.48) MAPTALDH1A1POLBKDM4ESMN1; SMN2
SCHEMBL6743539 0.77 CCNB2 (0.47) CDK1LMNAMAPK1MEN1KMT2A
SCHEMBL6739651 0.77 KMT2A (0.47) MAPTALDH1A1POLBKDM4EHSD17B10
SCHEMBL6741661 0.77 MAPT (0.41) MAPTALDH1A1SMN1; SMN2HSD17B10LMNA
SCHEMBL6740772 0.77 CHRM4 (0.56) MAPK1BCDIN3DTSHR
SCHEMBL6746105 0.77 MAPT (0.46) MAPTLMNADHFRMEN1KMT2A
SCHEMBL6740580 0.75 BCHE (0.51) MAPTALDH1A1HTTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818642-B2 CAMPYLOBACTER INFECTION TREATMENT ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040152714-A1 Benzylaminopyrimidines ALTANA PHARMA AG (DE) 2004-08-05 US disclosed
EP-1395594-A1 NEW BENZYLAMINOPYRIMIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2004-03-10 EP disclosed
WO-2002094832-A1 NEW BENZYLAMINOPYRIMIDINES ALTANA PHARMA AG (DE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152714-A1 Benzylaminopyrimidines DPYD, PGLS, TPMT MAPT 4405/4885ALDH1A1 355/4885HTT 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.